Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Negative predictive value of positron emission tomography/computed tomography in patients with a clinical suspicion of pancreatic cancer.

Lin JL, Barthel JS, Keshishian J, Eikman EA, Klapman JB.

Pancreas. 2011 Jul;40(5):653-6. doi: 10.1097/MPA.0b013e31821b5bf7.

PMID:
21602734
2.

Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.

Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.

Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14. doi: 10.1510/icvts.2009.227538. Epub 2010 Mar 2.

3.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
4.

Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules?

Hales NW, Krempl GA, Medina JE.

Am J Otolaryngol. 2008 Mar-Apr;29(2):113-8. doi: 10.1016/j.amjoto.2007.04.006.

PMID:
18314022
5.

Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.

Ann Surg Oncol. 2008 Jan;15(1):286-92. Epub 2007 Sep 20.

PMID:
17882493
6.

Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?

Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.

Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8.

PMID:
18330088
7.

Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound.

Schick V, Franzius C, Beyna T, Oei ML, Schnekenburger J, Weckesser M, Domschke W, Schober O, Heindel W, Pohle T, Juergens KU.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85. doi: 10.1007/s00259-008-0818-x. Epub 2008 May 15.

PMID:
18481063
8.

Positron-emission tomography and computed tomography of cystic pancreatic masses.

Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM.

Clin Radiol. 2007 Aug;62(8):745-51. Epub 2007 May 9.

PMID:
17604762
9.
10.

F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.

Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S.

J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9.

PMID:
15623441
11.

18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.

Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9.

PMID:
18043094
12.

The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.

Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH, Choi DW.

Pancreas. 2012 Aug;41(6):897-903. doi: 10.1097/MPA.0b013e318252f4f5.

PMID:
22699202
13.

Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.

Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, Schuller DE.

Laryngoscope. 2007 Jul;117(7):1173-9.

PMID:
17603315
14.

PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.

Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M.

Ann Surg Oncol. 2008 Sep;15(9):2465-71. doi: 10.1245/s10434-008-9992-0. Epub 2008 Jun 13.

PMID:
18551347
15.

Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.

Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD.

J Nucl Med. 1999 Nov;40(11):1784-91.

16.

Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.

Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T.

Ann Nucl Med. 2009 Jun;23(4):349-54. doi: 10.1007/s12149-009-0246-4. Epub 2009 Apr 2.

PMID:
19340526
17.
18.

The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.

Papós M, Takács T, Trón L, Farkas G, Ambrus E, Szakáll S Jr, Lonovics J, Csernay L, Pávics L.

Clin Nucl Med. 2002 Mar;27(3):197-201.

PMID:
11852308
19.

Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.

Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S.

Ann Surg. 2001 Nov;234(5):675-80.

20.

Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.

Buchs NC, Bühler L, Bucher P, Willi JP, Frossard JL, Roth AD, Addeo P, Rosset A, Terraz S, Becker CD, Ratib O, Morel P.

J Gastroenterol Hepatol. 2011 Apr;26(4):657-62. doi: 10.1111/j.1440-1746.2010.06525.x.

PMID:
21155879
Items per page

Supplemental Content

Write to the Help Desk